End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.14 CNY | +2.34% | +2.47% | +30.89% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.89% | 5.24B | D+ | ||
+21.85% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 290B | C+ | ||
+13.68% | 234B | B+ | ||
+3.65% | 198B | B- | ||
-11.12% | 194B | A+ | ||
+8.08% | 167B | C+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600566 Stock
- Ratings Hubei Jumpcan Pharmaceutical Co., Ltd.